I. Introduction T HREE glycoprotein hormones are synthesized and secreted by the pituitary under hypothalamic control. Two of them are the gonadotropins, LH and FSH, and the third one is TSH. During gestation in primates and equidaes an additional gonadotropin, CG, is secreted by the placenta.
Pituitary gonadotropins play pivotal roles in the control of reproductive function in both the female (1, 2) and the male (3) while the main role of TSH is in the control of thyroid gland activity (4). Although the human (h) and equine (e) CGs (the latter previously named PMSG) have been studied extensively, the full extent of their roles remains equivocal (5, 6).
Glycoprotein hormones form a family of structurally related molecules that are among the most complex molecules possessing hormonal activities. Despite their extensive homologies, these hormones exhibit high specificities, indispensable for their respective and often coordinated physiological roles. The present review is an attempt to summarize and interpret the available data concerning the molecular basis for their highly specific interaction with their receptors.
II. Primary Structure of Glycoprotein Hormones
Glycoprotein hormones are composed of two dissimilar subunits, named a and 0, that are associated by noncovalent bonds. Li and Starman (7) first discovered that the molecular weight of ovine (0) LH was lower at acidic pH than at neutral pH, suggesting that this hormone is a noncovalent dimer. Later, it was demonstrated that the two subunits in the dimer are different (8) and can be separated by counter-current distribution after acid dissociation (9). It was shown by De la Llosa and Jutisz (10) that the two subunits of oLH can be dissociated by 8 M urea and that biological activity is lost upon this dissociation but it can be recovered by noncovalent reassociation of the separated subunits. Subsequently, it was demonstrated that bovine (b) TSH (11) and oFSH (12) as well as hCG and eCG (13, 14) are also composed of two different non-covalently-bound subunits.
Pierce et al. (15, 16 ) separated the subunits of bLH and bTSH and determined their amino acid sequences. They discovered that LH and TSH share a common subunit that was subsequently named N. The history of these discoveries is narrated in a very recent article by Papkoff (17).
The a-subunit consists of a polypeptide chain of 92 residues in the human species and of 96 residues in other mammalian species. When all a-sequences are aligned using their highly conserved Cys residues (Fig. l) , the four residues missing in the human n-sequence correspond to positions 5-8 in all other species. For the sake of comparison and as previously proposed by Ward (18)) common numbering of sequences from different species will be used throughout this paper. Two oligosaccharide chains are N-linked on Asn residues a-56 and a-82, which are conserved in all mammalian species (19). Later, it had become evident that glycoprotein hormones in animals from all vertebrate classes consist of two dissimilar (W.1 subunits, one of which is structurally related to the mammalian common a-subunit (20).
Within each species the amino acid sequence of the o(-subunits of the different glycoprotein hormones was found to be identical (21). In fact, the a-subunits of all glycoprotein hormones are coded for by a single gene, separate from the P-genes, as first shown in the human species (22). This gene is expressed in the various pituitary and placental cells secreting the different glycoprotein hormones. Nevertheless, although n-subunits exhibit identical amino acid sequences in a given species, their N-linked oligosaccharide chains are generally different (23). Figure 1 shows that large portions of a-subunit polypeptide chains from 10 species (nine mammals and carp) are conserved. Seventy one of the 96 positions are occupied by the same amino acid residue in nine or 10 of the 10 species. The fact that the 10 half-cystine residues of all these molecules are conserved implies that the five disulfide bridges are most probably identical in all of them leading to a common folding of all a-subunits. This hypothesis is reinforced by the fact that hybrid heterodimers can be obtained with CY-and p-subunits from different species.
Because half-cystine residues in a-subunits are close to each other in two groups of two and two groups of three along the sequences, many difficulties have been encountered in the identification of the disulfide bridges in these molecules, and there is no agreement on the propositions forwarded by different laboratories (24). Even after extensive proteolysis of porcine (p) a-subunit with a cocktail of enzymes with various specificities (or with almost no specificity at all), its five disulfide bridges remain together with only a few other amino acid residues (25). This indicates that the pairings are not between the two groups of two half-cystines (Cys 11, 14 and Cys 63,64) on one hand and the two groups of three half-cystines (Cys 32, 34, 35 and Cys 86, 88, 91) on the other. The use of various chemical and enzymatic cleavages led to totally different assignments (25-27). In contrast, by using partial reduction and alkylation, two groups reached the same pairings for the five disulfide bridges in the n-subunits of bLH (28) and hCG (29), respectively. This convergence argues in favor of the latter propositions (shown in Fig. 1 ) provided that no disulfide interchange occurred under the reductive conditions used. This assignment, however, is not consistent with our observation that all five disulfide bridges remain together in the same peptide after trypsin and cyanogen bromide treatments of pLH a-subunit. Together these two treaments cleave polypeptide chains at the level of the a-carboxyl groups of Lys, Arg, and Met residues. In these conditions, a peptide (residues 9-15 + 34-39) containing only the two proposed S-S bridges Cys 11-Cys 35 and Cys 14-Cys 36 should have been obtained. It is not the case, perhaps because the Met 33-Gly 34 peptide bond is not cleaved by CNBr or because these assignments are not correct. This indicates that much uncertainty still exists in the determination of half-cystine pairings in a-subunits. Nevertheless, whatever the exact S-S pairings, the proximity of half-cystine residues along the a-polypeptide chain leads to the formation of a compact core.
Generally, polypeptide regions in proteins are conserved during evolution either because they are located at the surface of the protein where they exert a specific function or because they are buried inside the protein globule where mutations are more likely to disrupt the conformation of the molecule. In the a-subunit only the N-terminal sequence l-10 and the two short segments 68-72 and 77-81 appear to be free of evolutionary constraint. Thus it appears that strict constraints are exerted on a very large proportion of the N-chains. These constraints must be necessary for the conservation of the overall three-dimensional structure of the molecule, for the binding to the ,&subunits, for the binding to the receptors, and also for the possible nongonadotrope role of free N (30).
Of course, the hormone-specific P-subunits of glycoprotein hormones exhibit different amino acid sequences (Fig. 2) . The polypeptide chains of the P-subunits are made up of 110-111 residues (FSHs), 112-118 residues (TSHs), 117-121 residues (LHs), 145 residues (hCG), or up to 149 residues (eLH/CG). All of them possess 12 Cys residues at highly conserved positions among all sequences allowing their alignment. According to Ward et al. (18) , common numbering of all these sequences, as shown in Fig. 2 , will be used throughout this paper. The /.?-polypeptide chains bear one or two oligosaccharide chains N-linked on Asn residues in either position 13 or 30 or at both of them. hCG and eCGs and eLH P-subunits also bear O-linked oligosaccharide chains in their carboxy-terminal portion which is not present in the other molecules (31).
The 12 Cys residues in the P-subunits are more evenly scattered along their sequences than those in the LYsubunit. Nevertheless, there is agreement for only three of six bridges among all authors (23) even if the proposed pairings from two laboratories using different approaches were identical (32, 33). When site-directed mutagenesis was used to convert each Cys residue in hCG/3 to Ala or Ser (34), it was observed in several instances that individual P-subunits with one or the other mutated Cys residue of a suspected pair exhibited different foldings. Thus, although Cys pairing in P-subunits is less controversial than in a-subunits, some uncertainty remains. Since all but one P-subunit possess 12 Cys residues in strictly conserved positions, it is very likely that their pairings are identical in all hormones and consequently their overall three-dimensional structures are probably very similar or identical.
III. Functional
Structure of Native Glycoprotein Hormones All glycoprotein hormones consist of one common 01-subunit and one specific P-subunit, which are noncovalently associated. It has been demonstrated by different approaches (spectroscopic, physicochemical, immunological) that a conformational change occurs upon association of the subunits. It has been shown that after the initial association of the two subunits a conformational change affecting both of them leads to the "active" conformation of the hormonal heterodimer (35, 36).
Bousfield et al. (37, 38) have prepared LH hybrids by combining the eLH a-subunit and the eLH P-subunit with the corresponding subunits of oLH, pLH, and hCG. They observed that all the hybrids prepared with the eLHP-subunit were devoid of binding activity. One possible interpretation of these data is that after the initial association of eLH@ with a nonequine a-subunit, the conformational change of the dimer that gives rise to the active hormone does not occur. It seems that only the eLHa can promote and/or undergo the active conformational change with eLHP.
Many studies have been devoted to the determination of the polypeptide sequences in the o(-and P-subunits that are involved in their association. It has been demonstrated that the subunits of pLH can be covalently . This suggests that these two residues are close to each other at the surface of the LH molecule, at or near the interface of the two subunits. Although it is expected that the e-NH2 of the Lys a-49 residue is involved in this bridge, it has been shown that the Lys 48-Lys 49 bond in a-subunits is cleaved in a fraction of the molecules (see below) giving rise to a terminal free tu-NHz on Lys a-49. Therefore, it cannot be excluded that the amide linking is established between Asp p-111 and the a-NH2 of Lys a-49. Moreover, this cleavage might allow enhanced mobility of the newly formed Nterminal that would permit the reaction of Lys a-49 (either through its o(-or c-NH2) with a more distant residue than otherwise expected. Therefore, these data clearly demonstrate that a-49 and p-111 residues are located at the surface of the LH molecule, but it is possible that they are not as close as these data suggest.
Because of the heterogeneity or the overall negative charge of their carbohydrate moieties, it has not been possible to crystallize a native gonadotropin to determine its three-dimensional structure by X-ray diffraction. Crystallization of deglycosylated and desialylated hCG has been achieved recently (43, 44), and it is hoped that this success will permit the determination of its threedimensional structure in the near future. In the meantime, indirect evidence must be used to ascertain which part of each subunit is involved in the binding with its counterpart and with the receptor.
It was postulated very early that the invariable sequences among P-subunits were involved in the binding with the a-subunit, and experimental data have reinforced this view. Much less information is available concerning the polypeptide regions of the a-subunits that participate in binding with the P-subunits. It has been shown that the Lys-Ser bond at the C-terminus of the pLH a-subunit is sensitive to both trypsin and carboxypeptidase cleavages when the subunit is isolated while it is only sensitive to trypsin in intact pLH. This shows that this bond is at the surface of the LH molecule since it is cleaved by trypsin in both the free subunit and in the native hormone. This same bond is cleaved by carboxypeptidase in the free a-subunit but no longer cleaved in the native hormone (45). It is very likely that carboxypeptidase does not cleave this bond in the native hormone because the C-terminal carboxyl group is shielded from the medium when the P-subunit is associated with (Y and consequently it is not recognized as a C-terminus. It is possible that the P-subunit interacts directly with the C-terminus of the a-subunit but also that this Cterminus becomes buried during the conformational change of cy induced by p. The identification of the contact sites in the a-subunit of LH with its P-counterpart has also been attempted using the synthetic peptide approach (46, 47) (see below).
The association of subunits is fully reversible, and the dissociation constant of the equilibrium (Kd) has been determined for hCG, oLH, and pLH (48). The Kd values were found to be higher than the circulating levels of these hormones, indicating that their association is unstable when secreted. Nevertheless, their rates of dissociation are considerably lower than their rate of elimination from the circulation. Therefore, the hormones remain almost completely in their native dimeric form during the time they are present in the circulation.
IV. Structure of Glycoprotein Hormone Receptors
It is well established that the initial event in the regulation of target cells by glycoprotein hormones is their binding to specific receptors on the cell surface. Due to the extensive homology of the hormones of this family it was expected that their receptors would also share common structural features. Immunological evidence strengthening this view has been obtained. For example, selected monoclonal antibodies raised against the porcine testicular LH receptor are also able to bind to the pTSH receptor (49) indicating that they share at least one common epitope.
In the course of the purification and characterization of glycoprotein hormone receptors discordant data have been published. Some authors have claimed that the LH receptors are oligomeric, their subunits being associated by disulfide bridges (50-52), while others have reported that these receptors consist of only a single glycosylated polypeptide chain having a mol wt of 85-100 K (53-59). The receptor for FSH (240 K) has been described as being oligomeric, consisting of four subunits of similar mass (60 K) covalently linked by disulfide bridges (60, 61). The TSH receptor has also been described as an oligomeric molecule (62). A review of the data on the purification and structural characterization of the LH receptor appeared in 1989 (63).
Very recently, much progress has been made in our knowledge of glycoprotein hormone receptors with the reporting of the cloning of their full length complementary DNAs (64-78). The LH receptor cDNAs from porcine (64), rat (65), and human (66) species have been cloned and sequenced as has the rat LH receptor gene (67-69). The rat FSH receptor (70, 71) and canine (72), human (73-77), and mouse (78) TSH receptor cDNAs have also been studied.
From these data it has been elucidated that glycoprotein hormone receptors form a subfamily of G-proteincoupled receptors having a single polypeptide chain forming the typical seven hydrophobic oc-helices that constitute putative transmembrane segments (Fig. 3) . Using polyclonal antibodies raised against peptides corresponding to specific regions of the rat luteal receptor, it has been demonstrated that the N-terminal end of the molecule is located extracellularly while the C-terminus is located intracellularly (79). Glycoprotein hormone receptors all possess a large extracellular domain of approximately 340 (LH) to 390 (TSH) amino acid residues and three rather short connecting loops between transmembrane segments, also located extracellularly (80,81). It has been reported that the N-terminal domain of the LH receptor (exons l-10) is sufficient to bind the hor- hCG can be chemically deglycosylated with hydrogen fluoride (HF), and the resulting derivative (dg-hCG) has been shown to retain high affinity for rat testicular and ovarian LH receptors. Its binding activity was even higher (2-fold) than that of native hCG (nat-hCG) (91-93). However, in contrast to its binding activity, its in vitro stimulatory activity was considerably diminished though not completely abolished, and dg-hCG exhibited antagonistic activity toward nat-hCG in the stimulation of its target cells (94, 95). Similar results were obtained with dg-oLH which was 1.5 to 3-fold more active than nat-oLH in rat testicular and ovarian RRAs (96, 97). Upon HF deglycosylation, dg-oFSH was also found to exhibit a 2.5-fold increase in its binding activity toward bovine testicular membranes compared to nat-oFSH (98). Thus, it appears that not only does the removal of carbohydrate chains from gonadotropins not impair their binding activity but in contrast it increases their affinity for their receptors. Therefore the sugar moities in gonadotropins exert a partially inhibitory effect on their binding, and this inhibition appears to be due to the negative charge of their terminal residues. Indeed, desialylation of hCG (as-hCG), like its deglycosylation, leads to an increase in its binding activity with LH receptors (99). Interestingly, when eCG was desialylated with neuraminidase, the binding activity of as-eCG with rat testicular FSH receptors was increased 3-fold whereas its binding activity with LH receptors was increased lo-fold (100, 101). This is in agreement with previous data showing enhanced activity of as-eCG on rat Leydig and granulosa cells (102).
either gonadotropins or membrane preparations leads to enhanced interaction between hormones and receptors. This is probably because of diminished electrostatic repulsion between the negatively charged sugar residues in the two molecules. Compared to native eCG, as-eCG exhibited a greater increase in its binding to rat LH receptors (lo-fold) than to rat FSH receptors (3-fold) suggesting that LH receptors in rat testis bear more negative charges than FSH receptors (107).
In addition, treatment of desialylated rat luteal LH receptor with N-glycanase and endoglycosidase F provokes an additional drop in its apparent molecular weight and deglycosylated LH receptors show a major reduction in hCG binding (58). The conversion of Asn 173 in rat ovarian LH receptor by site-directed mutagenesis results in the total loss of hormone binding while the conversion of Asn 77 and Asn 152 provokes diminished binding to transfected cells (108). Similarly, the mutation of certain oligosaccharide-bearing Asn residues in recombinant human TSH receptor leads to the complete (Asn 77) or partial (Asn 113) loss of its affinity toward TSH (109). Mutation of the other four Asn is without effect. These data suggest that at least certain carbohydrate chains in LH and TSH receptors might be directly or indirectly involved in the binding of their specific ligand. However, it has been shown more recently (110) that desialylation or deglycosylation of the rat ovarian LH receptor does not impair the binding of hCG, as-hCG, or dg-hCG. Moreover, in the same study it was also demonstrated that the oligosaccharide chains in the receptor molecule are equally susceptible to glycosidase action in the presence or absence of bound hCG, indicating that hormonereceptor interaction only involves polypeptide portions of the receptor molecule.
Deglycosylated hTSH (dg-hTSH) obtained by HF treatment was shown to exhibit 6-fold greater binding affinity with porcine thyroid cell membranes than native hTSH (103). Similarly, dg-bTSH was more than twice as potent as native bTSH in a RRA using human thyroid membranes (104, 105). Thus, as with the gonadotropins, the carbohydrate chains in TSH seem to have an adverse effect on hormone-receptor interaction.
All these data indicate that the carbohydrate chains of the glycoprotein hormone molecules are distant from the hormone binding region and are not involved in the specific, high-affinity binding to their receptors. There is probably a repulsive effect between the terminal negative charges of the carbohydrate chains in the hormone and in the receptor and this, consequently, diminishes their affinity slightly. It is interesting to notice that a similar repulsive effect also exists between the LY-and psubunit of hCG, oLH, or oFSH since the stability of the dimers is increased in deglycosylated hormones compared to native hormones (111-114). Neuraminidase digestion of purified rat testicular and
In brief, it appears that gonadotropin sugar chains ovarian LH receptors led to a decrease in their apparent have no major role in the binding of gonadotropins to molecular weight showing that these molecules are siatheir receptors. Almost all authors agree, however, that lylated (55). The specific binding of ['251] hCG to neurathese carbohydrates are indispensable in the stimulation minidase-treated LH receptors from testicular and ovarof hormone target cells after binding to the receptors ian membranes was increased (106). Therefore, the re-(115-117). At variance with this idea is the claim that moval of negatively charged sialic acid residues from oLH and hLH, deglycosylated with endoglycosidase F, retain high steroidogenic activity on Leydig cells (118). The authors of this study advocate that HF treatment alters the polypeptide chains of gonadotropins and that the loss of stimulating activity in HF-treated LHs might arise from damage to their polypeptide chains rather than from removal of carbohydrate chains. However, this cannot be ascertained because the extent of carbohydrate removal was not checked. Moreover, peptide bond cleavages were found in only 45% of the HF-treated hCG molecules (44) while stimulating activity was almost completely abolished. Although one must be extremely careful to rule out that some properties of HF-treated gonadotropins do not arise from modification(s) of their polypeptide chains, it is much more likely that their loss of activity is due to their deglycosylation. In addition, it has been shown that dg-hCG subunits obtained by enzymatic treatment do recombine with their native counterparts and the reassociated hormones bind to LH receptors. The dg-a x nat-/3 recombinant binds equally well as the untreated hormone whereas the nat-ol X dgp recombinant exhibited a higher affinity for the receptors (95). HF and enzymatic deglycosylation have also been used to study the role of carbohydrates in TSH activity. Deglycosylation of hTSH and bTSH with HF does not impair binding to human thyroid membranes (103-105), and the removal of P-linked carbohydrate chain by enzymatic treatment of hTSH does not impair its in vitro biological activities (103, 119, 120). In contrast to dgbTSH, dg-hTSH was still able to stimulate CAMP production by thyroid cells but with slightly reduced potency compared to nat-hTSH (103). Nevertheless, dg-hTSH exhibited impaired activity on the growth of FRTL-5 cells (121).
Directed mutagenesis of hCG allowed expression of different recombinant hCG molecules in which each of the four carbohydrate chains was absent (117). It was found that none of them is required for binding but the one borne by Asn (~56 was found to be essential in the stimulation of hCG target cells. For several years, many studies have been devoted to the mechanisms of transmembrane signaling in gonadotropin target cells, but this is beyond the scope of this review.
The effect of desialylation and/or deglycosylation of glycoprotein hormones on their binding specificity has been studied by several groups. The concern of most studies has been the hCG molecule, which, upon desialylation or deglycosylation, has been found to exhibit enhanced binding activities toward TSH receptors (119, 122) and FSH receptors (123, 124) as well as toward LH receptors. The dg-hCG molecule, like as-hCG, shows a considerable increase (loo-fold) in its binding activity toward TSH receptors compared to nat-hCG (119).
Nevertheless, it must be pointed out that the binding potency of dg-hCG to TSH receptors is about 3000-fold less than that of bTSH.
The binding activity of dg-hCG toward ovarian rat FSH receptors has also been studied (124). Whereas nathCG displayed negligible binding potency compared to oFSH, dg-hCG was 5% as active as oFSH in the same RRA.
In brief, it appears that removal of sugar chains in hCG increases its binding to LH, TSH, and FSH receptors. The increase appears considerably higher toward TSH and FSH receptors (-loo-fold) than toward LH receptors (2-to 3-fold). Even so, the binding activities exhibited by dg-hCG toward TSH and FSH receptors are much lower than those of TSH and FSH, respectively. Thus, it seems that the presence of carbohydrate chains in hCG (particularly its terminal sialic acid residues) avoids the nonspecific low-affinity binding of hCG to non-LH receptors that is observed with dg-hCG. Consequently, carbohydrates in hCG play only a very marginal role in hormone specificity since even when they are missing, hCG exhibits a much higher affinity for LH receptors than for TSH or FSH receptors. Nevertheless, since during gestation plasma hCG concentrations can reach very high values, its possible thyrotropic and follicle-stimulating activities cannot be neglected (125, 126).
VI. Roles of cr and &Subunits in HormoneReceptor Binding
The roles of the common a-subunit and of the specific P-subunits in the specific binding of glycoprotein hormones to their respective receptors have been studied extensively by various analytical and experimental approaches.
A. Sequence analyses
Although the high affinity of the glycoprotein hormones for their receptors might be due to one (a or p) or both of their subunits, it is obvious that their binding specificity is due exclusively to their P-subunits whatever the mechanism by which this specificity is exerted.
As mentioned above, the amino acid sequences of o( and P-subunits that are available have been corrected and compiled recently by Ward and his colleagues (18) and are shown in Figs. 1 and 2 . In addition to the conservation of half-cystine residues in almost all /?-subunit sequences, it has been observed for a long time that some portions were also identical among all or nearly all glycoprotein hormone P-subunits. In eLH/CG P-subunit, the sequence 94-If these regions interact with the a-subunit they ob-96 is Gln-Ile-Lys while it is Arg-Arg-Ser or Arg-Leu-Ser viously will not be involved in the recognition of the for the other LHs and CGs and Asn-Ser-Asp or Asp-Serhormone receptor. In keeping with the hypothesis that Asp for the FSHs. According to the determinant loop conserved regions participate in intersubunit contact, it model, it is the net charge of this tripeptide that should has been found that two single Tyr residues in ovine and be responsible for the expression of either LH or FSH pLH P-subunits (in positions 37 and 59) were exposed to activity because the sequences are similar in the remainsolvent in the free subunit but were shielded after assoder of the loop for all FSHs and LHs. In the LHs the net ciation with the a-subunit (45, 127). These two residues charge of the 94-96 tripeptide is +l or +2 whereas it is belong to two of the highly conserved regions in all p--1 or -2 in the FSHs. The net charge of the tripeptide subunits [34-38 and 57-601 indicating that these two in eLH/CG is +l as for most LHs but the basic residue regions are indeed involved in the association with the (Lys 96) is different and in a different position than in a-subunit.
the nonequine LHs (Arg 94). In order to determine the sequences that might be involved in the specificity of glycoprotein hormones, the sequences have been compared across species so as to point out the structural features common for the different species that are specific for each hormone. By doing this, Moore et al. (128) have located the amino-acid residues within the disulfide bridge 93-100. They have proposed that the charge distribution in this peptide loop may determine the specificity of the hormone: a net charge of 0 or +l would lead to LH activity whereas a net charge of -3 would lead to FSH activity. This sequence has been named the determinant loop by these authors.
It is interesting to notice that this loop contains two residues [98-991 that are common to all hormones. These two residues might have been conserved during evolution because they participate in the binding with the a-subunit (see above). Alternatively, if the determinant loop hypothesis is correct, their presence might be crucial for the functional conformation of the loop.
In order to locate the sequences involved in the binding specificity of glycoprotein hormones, we have used a different reasoning. Since eCG and eLH possess both LH and FSH binding activities, we chose to compare their common P-sequence to those of the P-subunits of nine LHs, two CGs, and six FSHs as compiled by Ward and co-workers (18). The carboxy-terminal extension of eLH/CG is not responsible for its dual binding specificities (38) and, consequently, we only considered positions 1 to 117.
It has been suggested (128) that the double activity of eCG might be due to partial deamidation of Gln 94, introducing a new negative charge and consequently giving a net charge to the determinant loop intermediate between those of FSH and LH. Such modified molecules would exhibit some FSH activity in addition to (or instead of) LH activity. Such an hypothesis implies that two populations of eLH/CG molecules exist, one with LH activity only and another one with either FSH activity only or both LH and FSH activities. To date it has not been possible to separate eCG molecules having either LH or FSH activity when tested in nonequine species. Moreover, we have observed that all eCG preparations, regardless of their origin or their degree of purity, exhibit identical FSH/LH activity ratios (129). Several authors have reported that the FSH/LH ratio varied during gestation (5), but this can be easily explained by modifications in their sialic acid contents (see above) rather than by the postulated Gln 94 deamidation. Therefore, it is unlikely that the net charge of the tripeptide 94-96 is responsible for the dual LH and FSH activity in eLH/CG.
Among the 13 positions in eLH/CG P-subunits that are different from all other LHs and CGs (see above) we looked for similarities with 
B. Comparative approaches
It is impossible to give an exhaustive view of the comparative studies that have been performed to study the binding of glycoprotein hormones. Some of them have been done using hormones, hybrid hormones, and receptors from distant species such as fish and mammals or various other combinations (131-134).
More precise information can be drawn when the hormones and receptors come from more closely related species. Of course mammalian glycoprotein hormones have been studied in this way much more extensively than those from any other class. In most heterologous systems the different glycoprotein hormones retain their binding specificity and relative potency. Nevertheless, it is often observed in RRAs that heterologous hormones exhibit a higher affinity than the homologous hormone. For example, hCG has been described to have higher affinity for rat Leydig cell LH receptors than oLH (135), and its binding is almost completely irreversible in contrast to that of oLH. It was later observed that Na ions affected the binding of oLH but not that of hCG (136). In fact, kinetic studies of oLH and hCG binding in the presence and absence of Na ions indicate that the binding rates of both hormones are affected indicating that the high affinity of hCG for rat LH receptors is not due to the primary reversible interaction with the receptor but to a secondary irreversible change in the hormone-receptor complex (137).
In contrast to rat Leydig cell LH receptors, ovine testicular LH receptors have been shown to be unable to bind hormones other than oLH and bLH (138,139) and, in particular, hCG was found to have an extremely weak affinity for these receptors. Using ovine luteal cells, Niswender et al. (140) found that hCG exhibited highaffinity binding to LH receptors. Thus, very constrasting data are obtained according to the species and/or sex studied, illustrating that the systematic use of [lz51]hCG as the tracer in RRAs is questionable.
Strict binding specificities of glycoprotein hormones for receptors are generally conserved from one species to the other. The most remarkable exceptions so far known are the equine gonadotropins eCG and eLH. It has been known for a long time that eCG exhibits both LH and FSH activities in many mammalian species, and this property has been exploited for almost five decades (5).
Since several authors had reported that the mol wt of eCG is around 55-65 K (14,141,142), it could have been postulated that the eCG molecule is large enough to accomodate two binding sites (one for the FSH receptor and one for the LH receptor). In fact, in these studies the mol wt of eCG was largely overestimated. We have shown that its actual mol wt is more probably around 44 K (143), and this estimation is in good agreement with the subsequent chemical characterization of the hormone (144). Indeed, taking into account the molecular weight of the polypeptide part of eCG calculated from its amino acid sequence and the known proportion of carbohydrate in the molecule (-45%), the mol wt of the entire molecule falls very near 44 K.
More recently Bousfield et al. have demonstrated that the eCG P-subunit amino acid sequence is completely identical to that of the eLH P-subunit (145), and they have shown that the carboxy-terminal extension of the P-subunit is not involved in the binding of eCG and eLH to either LH receptors or FSH receptors (38). Indeed, an eLH derivative with a shortened P-subunit (a X 01-120) has been shown to be even slightly more potent than eLH itself in LH and FSH RRAs. Consequently, the additional FSH activity of eCG and eLH in heterologous species is determined by polypeptide regions in their flsubunits homologous to those existing in the pituitary gonadotropins from the other species.
It has been shown by several groups (100, 146-152) that eLH as well as eCG bind to FSH receptors from nonequine species but not to FSH receptors from the horse. Equine LH and CG exhibit binding activities toward FSH receptors from pig and rat that are approximately 15-25% that of the corresponding FSH's binding activity (147-149). Moreover, nonequine mammalian FSHs bind to horse FSH receptors as efficiently as to rat or pig FSH receptors (150-152) and, reciprocally, eFSH binds to nonequine FSH receptors with high affinity and stimulates the nonequine target cells (153-155). All these data clearly indicate that the high-affinity site for gonadotropins is very similar for horse FSH receptors and for the nonequine FSH receptors.
Since eCG and eLH bind to nonequine FSH receptors and stimulate the corresponding target cells, they obviously recognize the high-affinity sites present in both equine and nonequine FSH receptors. Why then don't they bind to equine FSH receptor? We have proposed that it is because this interaction is specifically inhibited in the horse.
It is unlikely that the mechanism of binding specificity similar regions within their structures. Since a-subunits are common to all of them, they should contribute in majority to the high-affinity site.
3) The specificity of each hormone is determined by inhibiting site(s) borne by its P-subunit. These sites impede the binding of each dimer to the receptors of the other hormones. As indicated above, we strongly suspect the P-subunit C-termini and particularly positions 102-103 to be involved in the building-up of the specific inhibitory sites. It can be suggested that the determinant loop described by Ward and his colleagues acts as an inhibitory site rather than as a recognition site.
This theory, i.e. the a-subunits hold the driving force for the association with receptors whereas the P-subunits control the specific access of the dimer, is in good agreement with data of Bousfield et al. (37,38). These authors have studied the binding activities of hybrids consisting of either the eLH a-subunit and the P-subunits from pLH, oLH, or hCG or the eLH P-subunit and the cysubunits from pLH, oLH, or hCG. They found that eLHol enhanced and eLH@ diminished the binding activities of the hybrids. These effects of eLHa and eLHP counterbalance each other when they are recombined as eLHcv X eLH& but each of them largely outdoes its counterparts from other species in cr/3 hybrids. Thus, somehow eLHcv conveys the strong affinity of the dimer for the receptors while eLHP inhibits binding. It seems, therefore, that the a-subunits in heterodimers play an essential role in the high-affinity binding of glycoprotein hormones toward their receptors while P-subunits somehow specifically limit this binding activity. Since free a-subunits are devoid of binding activity their association with P-subunits gives them, at the same time, the proper conformation for binding to the receptor (Fig. 4A ) and specific control of this binding (Fig. 4B) .
Papkoff and his colleagues (157, 158) showed that free eLH a-subunit binds with low affinity but significantly to FSH receptors in rat granulosa cells and inhibits the oFSH-stimulated secretion of plasminogen activator by these cells. In contrast, when the eLH a-subunit is recombined to the oLH P-subunit it is no longer able to inhibit the oFSH-stimulated secretion of plasminogen activator. This strongly suggests that the oLH P-subunit in eLHoc x oLHP inhibits the binding of the heterodimer to FSH receptors.
Consistent with the negative specificity hypothesis, it has also been shown that the binding activity of hCG is much higher for mouse TSH receptors than for human receptors (159). This suggests that the inhibition of binding of hCG to TSH receptors is less strict in a heterologous species than in the human species. This illustrates that separate selection occurred during evolution of the structures in glycoprotein hormones respon-sible for their binding specificity and those responsible for their high affinity toward their receptors. This probably permitted a diversification of specificities (and therefore a diversification of hormonal controls) without the need of a new high-affinity site. Our proposal that the high-affinity site in glycoprotein hormones is different and apart from their specificity sites appears reasonable.
C. Immunological studies
Polyclonal and monoclonal antibodies specific for the CY-or P-subunits of glycoprotein hormones have been used extensively to study the conformation of these hormones and to locate the regions involved in o( X p recombination or in the association with their receptors.
Many studies have been performed using hCG (160-170), and they have shown that the antibodies directed against the a-subunit appear to be much more effective in preventing hCG binding to LH receptors than are the antibodies directed against the P-subunits. Moreover, most of the antibodies made against the hCG a-subunit block the binding of the hormone to the receptor but fail to recognize hormone that is bound to receptors. The data concerning the effect of anti-hCGP antibodies on hCG-receptor interaction are more conflicting. Several groups have reported that most anti-hCGP antibodies do not inhibit the binding of hCG to LH receptors (160) and that these antibodies can bind to the hCG-receptor complex (171). Nevertheless, it has been indicated by a number of studies that certain anti-hCGP antibodies do inhibit hormone binding (160, 172). Taken on the whole these data indicate that the interaction of hCG with LH receptors involves its a-subunit more so than its psubunit.
We have studied monoclonal antibodies raised against native eCG and one has been found to be specific for eCG-0 but also recognizes the native LHs, CGs, and FSHs from all the species tested so far (172a). In addition, it inhibits eCG binding to bLH and bFSH receptors (Chopineau M, Maurel MC, Combarnous Y, Durand P., submitted) indicating that its epitope is a highly conserved structure at the surface of ,&subunits of all gonadotropins and that this region is involved in the recognition of the receptors. Another group of anti-eCG monoclonal antibodies have been found to be specific for a common epitope in eCGa. Like the P-specific antibody described above, they have been found to inhibit the binding of eCG to LH and FSH receptors. Moreover, their binding is inhibited in the presence of the P-specific antibody indicating that the two epitopes (one on the 01-and the other on 0) are close together. This invariable epitope of the P-subunit might participate in the constitution of the common nonspecific high-affinity site together with regions in the common a-subunit.
From immunological studies with hFSH (173-177) the importance of the a-subunit in the binding of the hormone to its receptors has also been put forward. Using a-subunits from various species, CNBr peptides from bovine and equine a-subunits and synthetic peptides, Ryan and his colleagues (168-170) found that the Cterminal end of the Q-subunit of hCG (predominantly residues 74-91) is a major antigenic determinant. In agreement with previous data, their results indicate that the hCGa C-terminus is important for hCG binding to LH receptors.
In hFSH, the same region has also been found to be antigenic and its occupation inhibits FSH binding to its receptors (177). Thus, the C-terminal end of the asubunits of gonadotropins appears to be involved in the recognition of the receptors by the native hormones. This conclusion is in agreement with the results of many studies on the enzymatic and chemical modifications of this region in various gonadotropins (see below).
Concerning TSH, the data obtained using antibodies directed against the cy or P-subunit led to conclusions that are totally at variance with those reached for hCG and FSH. Reports have been published that indicate monoclonal anti-TSHP antibodies inhibit bTSH binding to bovine thyroid receptors (178) and hTSH binding to FRTL-5 rat thyroid cells (179). In contrast, a-subunitspecific antibodies had little or no effect on hTSH binding suggesting that this subunit has no role in TSH binding (179). This radical difference between gonadotropins and TSH, as revealed by these immunological approaches, is difficult to explain and needs to be explored further.
D. Hormone-receptor cross-linking studies
Several laboratories have reported that both subunits of hCG can be cross-linked to LH receptors after binding of the hormone (54, 59, 180, 181). In contrast, others have found that hCG interacts mainly with the rat ovarian receptors through its a-subunit (53,183-184). These results were obtained by radiolabeling the N-and the /3-subunit of hCG with 1251 or 3H and recombining them with their nonradioactive counterparts. The resulting recombined hormone was allowed to bind to receptors, cross-linking was performed, and the resulting covalent linkages between hCG subunits and the receptor were deduced from their mobility in sodium dodecyl sulfatepolyacrylamide gel electrophoresis and/or by immunoblotting. These methods are difficult to handle and to interpret and the discrepancies between laboratories might stem from these technical difficulties. Neverthe-BINDING  SPECIFICITY  OF GLYCOPROTEIN  HORMONES  681 less, in all reports it is agreed that the common a-subunit is clearly directly involved in the association of hCG to LH receptors. Using the same approach for TSH, it was concluded that both the 01-and P-subunits are crosslinked to the TSH receptor (185).
E. Studies with synthetic peptides
Synthetic peptides having sequences spanning portions of the CY-or P-polypeptide chains from different hormones have been produced. Their affinities toward the different receptors have been studied in order to delineate the polypeptide portions involved in their recognition (186-194). It is well established that free CY-or P-subunits exhibit only very low binding activity if any. Consequently, only this marginal affinity of subunits toward receptors can be studied with the peptides. Moreover, the three-dimensional conformational changes induced by the noncovalent interaction of subunits is known to be of utmost importance for the subsequent high-affinity association with the receptors. It is obviously impossible to take into account the quarternary structure of the hormones by this technique. Then, it is not unexpected that these peptides exhibit very low affinities toward receptors compared to the native hormones. Indeed their affinities are at best lo5 times less than those of the native hormones.
Moreover, synthetic peptides are not glycosylated, and their affinities should be compared more appropriately to those of deglycosylated hormones. Since deglycosylated hormones exhibit enhanced binding to receptors compared to native hormones (see above), it appears that these peptides are at least lo6 to lo7 less active than the corresponding deglycosylated hormones. These extremely low affinities are comparable to those observed for the interaction of several other molecules such as dansyl-arginyl piperidine amide (195, 196) , aprotinin (197), and mouse epidermal growth factor (198) with the receptors of gonadotropins. It is very unlikely that the low-affinity binding of all these unrelated molecules is representative of the specific, high-affinity binding of glycoprotein hormones to their receptors. Extreme caution must thus be exercised in the interpretation of the data concerning the interaction of synthetic peptides with the glycoprotein hormone receptors if reliable information concerning the binding of native hormones is to be obtained.
Synthetic peptides representing sequences of both the <u-subunit and P-subunit of hCG have been found to inhibit hCG binding to rat ovarian membranes. Keutmann et al. (192, 193 ) prepared synthetic fragments corresponding to the intercystine loop 38-57 in hCGP and in hLHP. These peptides inhibited binding of [125I] hCG half-maximally at 1.51 X 10V4 M (hCG ,038-57) and 2.03 X lop5 M (hLH 038-57) respectively, whereas nathCG did it at 1.03 x 10-l' M. In a subsequent study (194) , these authors synthesized the peptides hCG p93-101 and hLH p93-101, including the intercysteine loop sequence that is postulated to determine hormone specificity (128). 193) is first that they used peptides in which the S-S bridges of the loops were not established and second that the p37-58 loop was split into two peptides. Nevertheless, in contrast to Keutmann et al., they found that hCG @l-16 was the sole active @peptide with a Kd around lop4 M.
The binding of hFSH P-subunit to FSH receptors has also been studied by this approach. It has been reported (198) that two tetrapeptides, TRDL and KTCT, present at positions 40-44 and 55-58 in the hFSH/3 sequence (Fig. 2) were able to inhibit [lz51]hFSH binding to calf testicular receptors. The TRDL sequence is also present in mouse epidermal growth factor, which has also been shown to bind to FSH receptors by these authors. The two tetrapeptides were potent at concentrations around lop2 M (201). A synthetic peptide encompassing the hFSHfl sequence 39-59 and including these two tetrapeptides, was found to be much more efficient in the inhibition of [1251]hFSH binding (Kd = 0.55 X 10M4 M) than each individual peptide and, in addition, it was found to stimulate estradiol biosynthesis in rat Sertoli cells (202, 203) . Another peptide corresponding to hFSH @87-101 was also reported to strongly (80%) inhibit [1251] hFSH binding at a millimolar concentration (202). However, it is also apparent from these data that 10 of the 11 peptides encompassing the whole hFSHp sequence elicited a significant inhibition of [1251] hFSH binding at 0.8 mM concentration.
Several synthetic peptides of the o-subunit of human glycoprotein hormones have also been found to inhibit the binding of hCG (186, 187, 190) or hTSH (188) to their respective receptors. Their affinities for the receptor are of the same order of magnitude as those of the /3-subunits (Kd of 1 to 20 X 10m5 M). Together, all the o(-peptides that have been reported by the two groups to inhibit hCG binding to LH receptors (~~21-35, cr31-45, cy41-59, ~~71-85, and ot81-92) represent almost two thirds of the a-subunit sequence, giving way to many possible hypotheses. A very recent report (187) has been devoted to the study of truncated peptides of the hCGa region 30-50 previously found to inhibit hormone binding to its receptors (see above). This study indicates that the CYregion 34-48 exhibits the same potency as the 30-50 peptide and that Arg a-39 and Phe a-37 are particularly important residues for this binding.
It is difficult to draw clear-cut conclusions from these inhibition studies carried out using synthetic peptides. Individual free subunits exhibit only marginal binding activity compared to native hormones. Moreover, this activity might be due to cross-contamination with the opposite subunit or native hormone. Therefore, peptide segments from the two subunits are needed together for expression of physiologically significant binding activity. It is thus not surprising that the affinity of synthetic peptides for hormone receptors is so weak. It is argued that the weak binding activity of synthetic peptides is not incompatible with their involvement in the highaffinity site of hormones because several individual weak sites would cooperate (multipoint attachment). Indeed several polypeptide portions of both subunits of glycoprotein hormones have been shown to be involved in receptor binding. Their individual affinities must be much less than that of the native hormones, but it cannot be symmetrically assumed with certainty that a peptide exhibiting low binding activity does belong to the hormone binding site. It has been clearly established that high-affinity binding activity of glycoprotein hormone is dependent on the conformational change taking place after their cy-and P-subunits associate (35,36). Then the mutual influence of several linear polypeptide portions appears to be of utmost importance in the constitution of the hormone high-affinity sites for the receptors even if each peptide alone is able to exhibit a specific threedimensional structure in solution. The interpretation of inhibition studies of hormone binding using linear synthetic peptides must thus be done carefully to rule out nonspecific effects. In this respect, it is important to point out that several groups have demonstrated that various synthetic peptides homologous to limited regions of LH or FSH CY-and @-subunits stimulate specific responses on their target cells (191, (203) (204) (205) . For these particular peptides, nonspecific interactions with the receptors are much more unlikely and it would be interesting to see whether they would cooperate efficiently when covalently linked.
F. Chemical and enzymatic modifications
A great number of chemical and enzymatic modification studies have been performed on glycoprotein hormones. An exhaustive review of the effects of chemical and enzymatic modifications of the functional groups on LH actions was published in 1985 (206). The general difficulty of these chemical and enzymatic modifications is that only amino acid or sugar residues with reactive groups can be studied and only their role can be appreciated. Moreover, it is generally difficult to obtain quantitative modifications at a unique site and extensive undesired modifications at other sites may also occur. In addition, discrete modification at a given site may induce conformational changes leading to distant effect. Nevertheless, a great body of information concerning the structure-function relationships of glycoprotein hormones has become available thanks to these techniques, in particular those concerning their association to their receptors.
As a general rule, it appears that modifications to the a-subunits of gonadotropins are more detrimental to the biological activity of hormones than modifications affecting the P-subunits. This may suggest that the 01-subunit has a prominent role in hormonal activity but it must also be pointed out that there are more modifiable residues in this subunit than in P-subunits.
It has been demonstrated that Tyr (r-21 is the residue most reactive to iodination and that its di-iodination did not impair the binding acivity of pLH (45). Stronger iodination conditions led to the di-iodination of Tyr (Y-92 and Tyr a-93 but this provoked the loss of hormonal activity. By contrast neither of the other two Tyr residues in cx (a-30 and (r-41) nor the two residues in p (p-37 and p-52) were accessible to iodination (45, 127). Likewise, it was later shown that the loss of binding activity of iodinated bLH was due to the cumulative effect of iodination on these three sites (207). Progressive nitration of Tyr a-21, (r-92, and a-93 in oLHa also led to a progressive decrease in the binding activity of recombined nitrated-a X native p (208). The nitration of the two Tyr residues [37 and 591 in free oLH/3 did not impede its recombination with p nor did it abolish the binding activity of recombined native o( X nitrated 0. Nevertheless, substitution of the hydroxyl group of Tyr p-37 with a dinitrophenyl group in pLH/3 still permitted its recombination with (Y but the hormone was inactive (209).
In many studies the substitution of the lysine residues in LH and hCG with basic groups (guanidination or acetimidation), neutral groups (alkylation, carbamylation), or acidic goups (acylation) has been considered.
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Gordon and Ward (206) concluded their extensive survey of the literature concerning these modifications by stating that lysine residues in the P-subunits play a less critical role and may be replaced entirely with other residues. Recently, conversion by site-directed mutagenesis of Lys cr-95 to Glu or Met in hCG was found to diminish the binding activity of the reconstituted hCG by only 15 or 50%, respectively (210). By contrast, the CAMP response in murine Leydig cells to these derivatives is abolished. When the Lys cr-95 is converted to Arg, no loss in both binding and stimulating activities is observed. This indicates that the positive charge in this position has no crucial role in the binding of hCG but it is involved in a subsequent step of transmembrane signaling. Free hCG/J can be phosphorylated by CAMP-dependent protein kinase (199) and the phosphorylation site has been found to be Thr b-97. In a subsequent paper from the same group (200), it has been demonstrated that the phosphorylation of this residue does not impede the recombination of the modified P-subunit with nathCGa. The binding activity of the recombined hormone to LH receptors was diminished to 29% of the activity of nat-hCG indicating that this residue might play a role in binding to the receptor. Because charge distribution in the peptide loop Cys /393-Cys PlOO was proposed to determine the specificity of the hormonal dimer (128), it was shown that the charge modification in the loop introduced by phosphorylation of Tyr p-97 (from +l to -0.6 at physiological pH) did not influence the LH/FSH activity balance. In fact, the marginal binding activity of hCG to FSH receptors was decreased by the same extent as its binding activity to LH receptors (199). Thus, this observation neither supports nor rules out the "determinant loop" hypothesis. Nevertheless, it clearly indicates that if charges in this loop are important for hormone specificity, they cannot be positioned at random.
The role of methionine residues in the binding of LHs to their receptors has also been studied (211-213). Cheng (211) has reported that carboxymethylation of Met N-S, (u-33, and p-52 in bLH is obtained preferentially and that this leads to the almost complete loss of binding activity. Using CNBr cleavage at the carboxyl side of Met residues, De la Llosa et al. (212) produced a "mutilated" oLH/3 in which the sequence 42-52 was missing. After recombination with native a, an active hormone was obtained indicating that this region (and particularly Met p-41 and Met p-52) of oLH/3 would have no primary role. More recently, a recombinant hCG was produced in which the methionyl residues were changed for selenomethionyl residues (213). Again, no drastic loss of activity was observed. Gordon and Ward (206) consider that methionine residues have no direct functional role in LH and that the loss of activity observed by Cheng upon carboxymethylation of three methionine residues in bLH is due to the deleterious effect of the introduction of negative charges.
There are only a few histidine residues in glycoprotein hormones. It is noteworthy that the three His residues in a-subunits are all in the C-terminal end at positions 83, 87, and 94. These His residues are highly conserved among all species except for the His-Tyr "transposition" between residues 87 and 93 in equine N (144,145) . There are no highly conserved histidine residues in the sequences of LH and CG /3subunits suggesting that these residues in p don't play a major role in LH binding. In contrast, there are three highly conserved His residues in the FSH P-sequences in positions 74, 75, and 89 and two in the TSH P-sequences in positions 75 and 102. In position p-74, histidine residues are found in all FSHs and also in several TSHs. In position p-75 histidine residues are found in all FSHs and TSHs and in position 89 histidine residues are present in all FSHs and several LHs and CG. Thus, none of these positions appears to be highly specific for one activity. By contrast, the presence of a His residue in position p-102 is unique to TSH molecules. We have pointed out previously that this position is occupied by a valine residue in all the hormones exhibiting FSH activity (all FSHs but also eCG and eLH). This suggests that this position might be important not only for the FSH us. LH specificity of gonadotropins but also for TSH specificity.
Chemical modification of His residues in different LHs and in eCG leads to loss of their binding activity (214, 215). Because of the His-Tyr transposition at positions 87-93 between the equine and the other a-subunits, His a-83 and His a-94 remain the only His residues conserved in all species. Two groups have studied the environment of His residues in native LH or hCG and their subunits by 3H nuclear magnetic resonance spectroscopy (216, 217). Their data are consistent with these residues having a primary role in hormone binding. More recently, it has been proposed that His a-94 is directly involved in hormone binding and on the basis of analogy with the substrate pocket of serine proteases, it is hypothesized that His a-83 participates in the activation of target cells through a mechanism similar to the one observed for these enzymes (218). This view is consistent with the observations that protease inhibitors inhibit hCG action and that chymotrypsin potentiates hCG action (195) (196) (197) . Whatever the mechanism, it appears that His residues in positions a-83 and a-94 play an important role in hormone binding and action.
The modification of carboxylic groups of aspartic acid and glutamic acid residues in LHs from different species has been studied by several groups (39-42, 219). The substitution of numerous carboxylic groups produces inactive hormones because of the dissociation of subunits. We have demonstrated that it is possible to obtain active pLH with covalently linked a-and P-subunits by using a low concentration of carbodiimide in the absence of added nucleophile (39). This method has since been shown to be applicable to many other glycoprotein hormones. Weare and Reichert (42) identified Lys a-49 and Asp p-111 as the residues involved in the intersubunit bridge. These residues are thus located at the surface of the LH molecule at or near the cu-p interface. Since the disappearance of their charges does not prevent hormone binding, it seems unlikely that they interact with the receptor.
In several studies, the subunits of glycoprotein hormones have been digested with proteolytic enzymes in order to observe the effect of the removal of polypeptidic portions and/or the cleavage of unique peptide bonds on binding to receptors. The heterodimer constituted by the native a-subunit and tryptic P-core of hCG retained little (0.1%) LH-receptor binding activity compared to nathCG (220). This derivative contained the whole p-sequence except the N-terminal dipeptide and the C-terminal extension [fl115-1451, the latter being known not to play any role in this respect in hCG (221) or in eCG and eLH (38, 150). It seems that the loss of binding activity in this hCG derivative is due to the few peptide bond cleavages in its sequence between residues p-43 and p-44, p-74 and p-75, and between p-95 and p-96. The same seems to be true for oLH digested with endoproteinase C having a single cleaved peptide bond at either side of Arg p-43 (222), this being only 2% as active as native oLH. Likewise, cleavage of the bond between Gly 47 and Val 48 in hCGp (223, 224) led to an almost complete loss of its binding activity. Since no amino acid residues were missing in these derivatives, it seems that the loss of activity occurred because the cleavage(s) in the P-sequence no longer permitted the correct conformational change in the a$-dimer. This confirms that the building up of the functional binding site involves direct or indirect participation of large portions of the two subunits. Incidentally, these data are at variance with those of De la Llosa et al. (210) who reported that a recombined hormone dimer with a P-subunit in which the 42-52 region was missing was still active.
By using carboxypeptidases it has been shown that the C terminus of the a-subunit plays an important role in receptor binding of gonadotropins (45, 225) . These data are in agreement with the observation that iodination or nitration of Tyr a-92 and/or Tyr a-93 alters the binding potency of these hormones (45, 127, 208).
G. Site-directed mutagenesis
Recently site-directed mutagenesis techniques have been introduced in the study of structure-function relationships of glycoprotein hormones (130, 208, 226, 227) . Concerning the study of the specificity of these hormones, a very elegant study has been published recently by Campbell et al. (130) who constructed chimeric ha X hCGP/hFSH/? molecules and determined their immunological and in vitro biological properties. By this technique they replaced short sequences in hCG/3 by the corresponding sequences in hFSH/3 and tested the potency of the chimeric recombinant molecule in LH and FSH RRAs. The chimeric molecules containing the OFSH 39-58 sequence did not exhibit any FSH binding activity, this being at variance with the proposals made from the synthetic peptide approach (see above).
By contrast, they found that the (a) x (PhCG 1-93 + phFSH 94-114 or 117) chimeric heterodimers exhibited FSH receptor binding instead of LH receptor binding activity. As the FSH sequence 93-100 proposed by Moore and Ward as the determinant loop is included in this chimeric molecule with FSH activity, it seemed possible that this region was indeed responsible for the binding specificity of gonadotropins. However, the (a) X (phCG l-93 + PhFSH 94-97 + PhCG 98-114) chimeric heterodimer containing the four FSH-specific residues of this loop still exhibited LH activity but no FSH activity. This result does not rule out participation of the /393-100 region in hormone specificity but it does not support a major role in this function either.
Moreover, the (o() x (PhCG l-107 + @hFSH 108-114) was also found to retain LH activity with no FSH activity. The comparison of the binding activities of the three "hCG" molecules containing the sequences OhFSH 94-114 (FSH binding), PhFSH 94-97 (LH binding), or phFSH 108-114 (LH binding) suggests that the /398-107 sequence is particularly important to binding specificity. Nevertheless, it must be emphasized that amino acid residues belonging to the sequences @FSH 94-97 and pFSH 108-114 must be present together in the molecule for the expression of FSH activity. It is also important to determine whether the appearance of FSH binding activity in the recombinant hCG molecule containing the phFSH 94-114 sequence is actually due to its presence or to the absence of the corresponding sequence of hCG.
It is noteworthy that the Val plO2 residue that we have proposed as a possible FSH-determinant in eCG (see above) belongs to the p98-107 sequence pointed out by Moyle and colleagues. Although this agreement is encouraging, it must be taken into consideration that the hCG/hFSH chimeric molecules express either LH or FSH binding activity toward rat luteal receptors. By BINDING SPECIFICITY OF GLYCOPROTEIN HORMONES 685 contrast, eCG expresses both LH and FSH activities in rat testicular and ovarian RRAs (154).
We have mentioned that site-directed mutagenesis or expression of recombinant chimeras have also been utilized for the study of glycoprotein hormone receptors (86-89, 108, 228-230). This approach is obviously very promising for the study of structure-function relationships of glycoprotein hormones and their receptors but it has several limitations. First, recombinant hormones can generally be obtained only in very small amounts and, therefore, their concentrations in RRAs or in vitro bioassays must be previously quantified by immunoassays; this quantification can be distorted by altered interaction with antibodies. Moreover, the very limited availability of recombinant hormones precludes the study of their physico-chemical properties. Finally, recombinant molecules are generally expressed in cells different from those that normally produce them; and consequently the structure of their polysaccharide chains can be different from that observed in pituitary or trophoblastic cells. Despite these limitations, it can be expected that site-directed mutagenesis will be extremely powerful and increasingly used in the near future to decipher the molecular mechanisms of the specificity and affinity of the interaction of glycoprotein hormones with their receptors.
VII. Concluding Comments
Although much progress has been made in our knowledge of structure-function relationships of glycoprotein hormones during the last few years, there are still many controversial data and hypotheses concerning the molecular bases of binding specificity of these hormones.
Our personal view (schematized in Fig. 4 ) is that 1) the glycoprotein hormone common a-subunit is responsible for the hormones' high-affinity for their receptors, 2) P-subunits induce the functional conformation of the cu-subunit, and 3) that the different P-subunits specifically inhibit the binding of each heterodimer to the receptors of the other hormones (negative specificity).
The C-terminal region of P-subunits and particularly residues in positions 102-103 (Gly-Pro in LHs, Val-Arg in FSHs) would have an essential role in this mechanism.
Obviously, much work by different approaches is still needed to test this working hypothesis. It is inherent to the model that the absence of the inhibitory site(s) in the P-subunits should provide a multifunctional hormone. The site-directed mutagenesis approach should be extremely helpful in this regard. 
